reports
ChemoMetec A S: 2 directors
Two Directors at ChemoMetec A S bought 1,817 shares at between 684.000DKK and 704.000DKK. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Indberetning af ledende medarbejderes transaktioner
Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 298 7. november 2025 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af CFO Kim Nicolajsens transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20 Om ChemoMetec A/S Chemo...
Notification of managers’ transactions
Notification of managers’ transactions ANNOUNCEMENT NO. 298 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CFO Kim Nicolajsen in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec dev...
Indberetning af ledende medarbejderes transaktioner
Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 297 7. november 2025 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af administrerende direktør Martin Helbo Behrens’ transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20 ...
Notification of managers’ transactions
Notification of managers’ transactions ANNOUNCEMENT NO. 297 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CEO Martin Helbo Behrens in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 About ChemoMetec A/S ChemoMet...
Vækst i omsætning og driftsresultat
Vækst i omsætning og driftsresultat Periodemeddelelse for 1. kvartal 2025/26 (1. juli - 30. september 2025) Vækst i omsætning og driftsresultat Omsætningen steg i 1. kvartal 2025/26 med 8% (11% ved faste valutakurser) til DKK 124,6 mio. fra DKK 115,6 mio. i samme periode sidste år. Udviklingen afspejler en fortsat fremgang i omsætningen af både instrumenter, forbrugsvarer og serviceydelser. ChemoMetec oplever endvidere en stigende interesse for vores teknologi, herunder ikke mindst XcytoMatic-platformen, og det forventes, at denne udvikling vil fortsætte og påvirke salg og indtjening posi...
Growth in revenue and operating profit
Growth in revenue and operating profit Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 115.6 million in the year-earlier period. The Q1 performance reflected continued growth in sales of instruments, consumables and services. Moreover, ChemoMetec is experiencing growing interest in its technology, not least the XcytoMatic platform, and this trend is expected to continue, affecting sales and earnings positively, particularly in the latter pa...
Opjustering
Opjustering MEDDELELSE NR. 295 28. oktober 2025 Opjustering ChemoMetec oplever en stigende interesse for sin teknologi, herunder ikke mindst XcytoMatic platformen, og forventer som følge heraf en positiv udvikling i salg og indtjening i særligt den sidste del af regnskabsåret 2025/26. Der forventes således nu en omsætning i regnskabsåret 2025/26 på DKK 565-580 mio. mod senest udmeldt DKK 545-565 mio. mens EBITDA forventes at ligge i intervallet DKK 320-335 mio. mod senest udmeldt DKK 295-315 mio. ChemoMetecs periodemeddelelse for 1. kvartal 2025/26 forventes offentliggjort den 6. nov...
Upgrade of guidance
Upgrade of guidance ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26. Consequently, revenue in the financial year 2025/26 is now expected to be DKK 565-580 million against the most recently announced DKK 545-565 million, while EBITDA is expected to be in the range of DKK 320-335 million compared to the most recently announced DKK 295-315 million. ChemoM...
Forløb af ordinær generalforsamling
Forløb af ordinær generalforsamling MEDDELELSE NR. 294 9. oktober 2025 Forløb af ordinær generalforsamling Den ordinære generalforsamling i ChemoMetec A/S blev afholdt den 9. oktober 2025 kl. 17.30 hos Nordsjællands KonferenceCenter. På generalforsamlingen blev bestyrelsens beretning om selskabets virksomhed i det forløbne år fremlagt, årsrapporten for 2024/25 blev godkendt, og bestyrelsen samt direktionen blev meddelt decharge. Generalforsamlingen godkendte det af bestyrelsen fremsatte forslag om udlodning af udbytte på DKK 7 pr. aktie a nominelt DKK 1. Bestyrelsens forslag om, ...
Procedure of the Annual General Meeting
Procedure of the Annual General Meeting ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2024/25 was approved, and the Board of Directors and the Executive Board were granted discharge. The Annual General Meeting approved the proposal of the Board of Directors to distribute a dividend of DKK ...
Indkaldelse til ordinær generalforsamling 2025
Indkaldelse til ordinær generalforsamling 2025 MEDDELELSE NR. 293 17. september 2025 Indkaldelse til ordinær generalforsamling Vedlagt offentliggøres selskabets indkaldelse til ordinær generalforsamling, som afholdes torsdag den 9. oktober 2025 kl. 17.30. Generalforsamlingen afholdes hos Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød. Yderligere oplysninger Kim Nicolajsen, CFO Telefon (+45) 48 13 10 20 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrumenter til celletælling og en lang række andre målinger. ChemoMetecs instrumenter markedsf...
Notice of Annual General Meeting 2025
Notice of Annual General Meeting 2025 ANNOUNCEMENT NO. 293 17 September 2025 Notice of Annual General Meeting Notice is hereby given of the Annual General Meeting, which will be held on Thursday 9 October 2025 at 5.30 p.m. The general meeting will be held at Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød Additional info Kim Nicolajsen, CFO Telefon (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, bi...
Årsrapport 2024/25 - Vækst i omsætning og EBITDA
Årsrapport 2024/25 - Vækst i omsætning og EBITDA MEDDELELSE NR. 292 11. september 2025 Årsrapport 2024/25 (1. juli 2024 - 30. juni 2025) Vækst i omsætning og EBITDA ChemoMetecs omsætning steg i 2024/25 med 22% til DKK 495,6 mio., og driftsresultatet (EBITDA) viste en fremgang på 39% og blev på DKK 258,0 mio. Den positive udvikling i omsætningen afspejler en stigning i salget af både instrumenter, forbrugsvarer og serviceydelser. Lanceringen af de nye XcytoMatic-produkter forløber tilfredsstillende. ”Samtidig med vores store fokus på igen at skabe vækst i den eksisterende forret...
Annual Report 2024/25 - Growing revenue and EBITDA
Annual Report 2024/25 - Growing revenue and EBITDA ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating profit (EBITDA) increased by 39% to DKK 258.0 million. The positive revenue performance reflected an increase in sales of both instruments, consumables and services. The launch of the new XcytoMatic products is proceeding as planned. “Along with our strong focus on creating renewed momentum in our existing business, we spent considerable re...
Forventninger til regnskabsåret 2025/26
Forventninger til regnskabsåret 2025/26 MEDDELELSE NR. 291 11. september 2025 Forventninger til regnskabsåret 2025/26 ChemoMetec har i dag godkendt årsrapporten for 2024/25, herunder forventningerne til 2025/26, som vurderes at udgøre intern viden. ChemoMetec forventer i 2025/26 en omsætning i niveauet DKK 545-565 mio. (2024/25: DKK 495,6 mio.) og et driftsresultat (EBITDA) i niveauet DKK 295-315 mio. (2024/25: DKK 258,0 mio.). Årsrapporten for 2024/25 offentliggøres samtidig med denne meddelelse, og der er heri redegjort for forudsætningerne for forventningerne til 2025/26 (s. 39-4...
Guidance for the 2025/26 financial year
Guidance for the 2025/26 financial year ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million). The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidan...
Foreløbige tal for omsætningen i regnskabsåret 2024/25
Foreløbige tal for omsætningen i regnskabsåret 2024/25 MEDDELELSE NR. 290 1. juli 2025 Foreløbige tal for omsætningen i regnskabsåret 2024/25 På baggrund af de foreløbige regnskabstal forventes ChemoMetec at omsætte omkring DKK 496 mio. i regnskabsåret 2024/25, mod tidligere udmeldt DKK 470-490 mio. ChemoMetecs årsrapport for 2024/25 forventes offentliggjort den 11. september 2025. Yderligere oplysninger Martin Helbo Behrens, CEOTelefon: (+45) 48 13 10 20 Kim Nicolajsen, CFOTelefon (+45) 48 13 10 20 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrum...
Preliminary revenue figures for the 2024/25 financial year
Preliminary revenue figures for the 2024/25 financial year ANNOUNCEMENT NO. 290 1 July 2025 Preliminary revenue figures for the 2024/25 financial year Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million for the financial year 2024/25, against the previously announced DKK 470-490 million. ChemoMetec’s annual report for 2024/25 is scheduled to be released on 11 September 2025. Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec deve...
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK640.00) - Solid Q3, but with mixed elements
With c26% revenue growth, Q3 was stronger than expected, with a solid beat on recurring revenue lines, although instruments fell just shy of our forecast, mainly related to new product launches that, despite a significant rise in customer validations in progress, take time. The maintained guidance implies only c5% YOY growth in Q4, but we believe management is being conservative. We reiterate our BUY and DKK640 target price.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.